Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion.
D015068:17-Ketosteroids / Q000652:urine; D000305:Adrenal Cortex Hormones / Q000652:urine; D001943:Breast Neoplasms / Q000188:drug therapy*; D002118:Calcium / Q000652:urine; D002986:Clinical Trials as Topic; D003345:Corticosterone / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D005260:Female; D006062:Gonadotropins / Q000652:urine; D006801:Humans; D007986:Luteinizing Hormone / Q000652:urine; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D011189:Potassium Chloride / Q000627:therapeutic use; D011276:Pregnanediol / Q000652:urine; D013778:Tetrazolium Salts / Q000652:urine
D015068:17-Ketosteroids; D000305:Adrenal Cortex Hormones; D006062:Gonadotropins; D013778:Tetrazolium Salts; D011189:Potassium Chloride; D007986:Luteinizing Hormone; D003404:Creatinine; D008525:Medroxyprogesterone; D011276:Pregnanediol; D002118:Calcium; D003345:Corticosterone